A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea
Completed · Phase 1
Conditions studied: Cryptosporidiosis, HIV Infections
In brief
To determine the safety and effectiveness of intravenous spiramycin in patients with AIDS-related cryptosporidial diarrhea. Spiramycin, a macrolide antibiotic, has been studied in the United States for the treatment of cryptosporidial diarrhea. Some reports suggest that spiramycin is useful in improving the symptoms of cryptosporidial diarrhea in some patients. Results of one study, however, showed no significant difference between spiramycin and placebo (inactive medication). A later study indicated that the absorption of spiramycin is significantly decreased when food is present. Thus, the results of the trial may have been due to poor absorption of spiramycin.
Key facts
- Study ID
- NCT00000980
- Run by
- Rhone-Poulenc Rorer
- People needed
- 25
- Last updated by the study team
- 2005-06-24
Who can join
Age: 13 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Concurrent Medication:
- Allowed:
- Vitamin supplements.
- Zidovudine (AZT) for patients previously taking AZT. However, dosing with spiramycin should be delayed until the dose of AZT has stabilized. The dose may be decreased for AZT-associated toxicity.
- Allowed for diarrhea:
- Loperamide hydrochloride capsules (2 mg) or loperamide hydrochloride liquid (1 mg/5 ml).
- Allowed for nausea:
- Sucralfate and metoclopramide hydrochloride.
- Allowed for vomiting:
- Prochlorperazine and trimethobenzamide hydrochloride.
- Allowed as prophylaxis for Pneumocystis carinii pneumonia (PCP):
- Aerosolized pentamidine.
- Patients must have:
- A diagnosis of AIDS according to the CDC.
- Chronic diarrhea.
- Presence of Cryptosporidium oocysts in stool specimen. Patients or a legally authorized representative must sign an informed consent form. Diet will be lactose free, maximum 7 g fat/day with unlimited calorie intake. Patients who require total parenteral nutrition will also be allowed oral intake.
You may not qualify if…
- Co-existing Condition:
- Patients with the following are excluded:
- Grade 4 (for hematologic) or Grade 3 (for all other) toxicity.
- Known sensitivity to macrolide antibiotics.
- Presence of other diarrhea-causing pathogens.
- Active opportunistic infection requiring systemic antimicrobial therapy.
- Toxicity grades according to NIAID toxicity scale for adults.
- Concurrent Medication:
- Excluded:
- Other investigational drugs.
- Cancer chemotherapy.
- Alpha interferon.
- Other immunomodulating agents.
- Other macrolide antibiotics.
- Trimethoprim / sulfamethoxazole.
- Ganciclovir.
- H2 blockers and AL-721.
- Medications known to cause gastrointestinal irritation or alteration of gastrointestinal motility or absorption should be avoided if possible.
- Zidovudine (AZT) therapy may not be initiated and the dose may not be increased during the study.
- Patients with the following are excluded:
- Grade 4 (for hematologic) or Grade 3 (for all other) toxicity.
- Known sensitivity to macrolide antibiotics.
- Presence of other diarrhea-causing pathogens.
- Active opportunistic infection requiring systemic antimicrobial therapy.
- Toxicity grades according to NIAID toxicity scale for adults.
Where it is running
- Kaiser Permanente Med Ctr — San Diego, California, United States
- Johns Hopkins Univ School of Medicine — Baltimore, Maryland, United States
- Univ of Massachusetts Med Ctr — Worcester, Massachusetts, United States
- Bellevue Hosp / New York Univ Med Ctr — New York, New York, United States
- Cornell Univ Med Ctr — New York, New York, United States
- Univ Hosp of Cleveland / Case Western Reserve Univ — Cleveland, Ohio, United States
- Nelson Tebedo Community Clinic — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.